Theriva Biologics, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Theriva Biologics, Inc. (TOVX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-08-11
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-06-30 was $0.00.
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-03-31 was $0.00.
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $1.32M.
- Theriva Biologics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month as first filed | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $1.30M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $1.30M derived: sum of 3 quarters · filed 2026-05-05 | $5.40M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.30M derived: sum of 2 quarters · filed 2026-03-12 | $5.40M derived: sum of 3 quarters · filed 2026-03-12 | $1.32M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $1.30M 10-K · filed 2026-03-12 | $1.32M 10-Q · filed 2024-11-12 | $5.40M derived: sum of 2 quarters · filed 2026-03-12 | $1.32M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $4.10M 10-K · filed 2025-03-06 | $0.00 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |